Moderna (MRNA) Q2 FY26 earnings call

Moderna delivered Q2 FY26 results above revenue guidance, demonstrating continued financial discipline with reduced cash costs and operating expenses. The company advanced its infectious disease and oncology pipelines, securing a positive VRBPAC recommendation for its flu vaccine and presenting durable data for its individualized cancer therapy. While the norovirus vaccine trial faced a setback, Moderna remains focused on upcoming regulatory decisions and pipeline readouts, preparing for a broader portfolio and geographic expansion in the coming years.